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Jae Hyuk Do1, Yoo Shin Choi2* and Eun Young Ze1Abstract
Background: Cystic duct adenocarcinoma is a rare disease because the cystic duct has a short length and a narrow
cavity. Cystic duct adenocarcinoma accounts for 8% of all gallbladder adenocarcinoma; of these, adenocarcinoma
that develops from the remnant cystic duct after cholecystectomy is extremely rare. We report a case of incidentally
detected adenocarcinoma that developed from the remnant cystic duct in a patient with history of cholecystectomy.
Case presentation: A 74-year-old Korean woman visited our hospital with abdominal pain. Her past medical history
included cholecystectomy for acute cholecystitis with gallstones 10 years previously. Imaging of the abdomen
demonstrated inflammation of the remnant cystic duct with multiple impacted stones. Complete removal of the
remnant cystic duct with stones was performed. The pathologic report showed severe inflammation with abscess
formation and an unexpected adenocarcinoma that appeared to invade the perimuscular connective tissue. The
second operation (confirmation of the resection margin of the remnant cystic duct, wedge resection of the liver,
and lymphadenectomy) was performed due to suspicion of pT2. There were no cancer cells in the resection margin of
the remnant cystic duct, liver, or lymph nodes (0/6). The final histopathological diagnosis was pT2N0M0. She recovered
without any complications. The patient is still living 1 year after surgery without recurrence or metastasis.
Conclusions: We report a rare case of adenocarcinoma that developed from the remnant cystic duct in a patient who
underwent cholecystectomy.
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Cystic duct adenocarcinoma is a rare disease because
the cystic duct is anatomically short in length and has
a narrow cavity [1,2]. When the narrow lumen of the
cystic duct becomes obstructed, symptoms such as ab-
dominal pain or jaundice may develop early and the
prognosis may be quite favorable; however, later on, the
tumor seems to behave like bile duct carcinoma [3]. The
remnant cystic duct (RCD) is not protected from carcin-
oma, although this is an extremely rare occurrence com-
pared to malignancy of the intact cystic duct. We report
a very rare case of incidentally detected adenocarcinoma
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A 74-year-old Korean woman was admitted to our hos-
pital with right upper quadrant (RUQ) abdominal pain,
nausea, and vomiting which began the preceding day.
She had no smoking history or significant family history.
Her past medical history included cholecystectomy for
acute cholecystitis with gallbladder (GB) stones 10 years
prior. At that time, the pathologic report was inflamma-
tion of the GB. Two years before admission, a computer
tomography (CT) scan of the abdomen performed for
routine screening revealed two small stones (4 mm,
3 mm) in the RCD, and two small stones (3 mm, 2 mm)
in the distal common bile duct (CBD). Endoscopic retro-
grade cholangiopancreatoscopy (ERCP) was performed,
and the two CBD stones were removed. At that time,
surgery was recommended for the RCD stones, but the
patient refused the operation.
At admission, she was afebrile and physical examin-
ation showed tenderness of the RUQ of the abdomen.
Blood test and laboratory data indicated an elevatedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Do et al. BMC Gastroenterology 2014, 14:175 Page 2 of 4
http://www.biomedcentral.com/1471-230X/14/175white blood cell count (10360 μl−1; normal < 9000 μl−1)
and elevated serum concentrations of high sensitivity C
reactive protein (22.98 mg/L; normal < 1.0 mg/L). How-
ever, the serum concentrations of total bilirubin, alanine
aminotransferase, and alkaline phosphate, as well as
tumor markers, including carcinoembryonic antigen and
carbohydrate antigen 19–9 were within the respective
normal ranges. Both CT scan and magnetic resonance
imaging of the abdomen demonstrated inflammation of
the RCD with multiple impacted stones (Figure 1).
Complete removal of the RCD was performed with a
preoperative diagnosis of inflammation of the RCD and
multiple impacted stones. The size of the excised RCD
was 2 cm × 1 cm and the wall was thick. There were
multiple stones (1 cm × 1, 2 ~ 3 mm × 5) and pus-like
bile. The pathologic report indicated chronic active in-
flammation with abscess formation and adenocarcinoma
that appeared to invade the perimuscular connective tis-
sue (Figure 2). On positron emission tomography CT
scan, there was no evidence of metastasis.
The second operation was planned due to suspicion of
pT2. Confirmation of the resection margin of the RCD,
wedge resection (segment 4b and 5) of the liver, and
lymphadenectomy were performed. There were no can-
cer cells in the resection margin of the RCD, liver, or
lymph nodes (0/6). The final histopathological diagnosis
was pT2N0M0. The patient recovered without any com-
plications, and is still living 1 year after surgery without
any recurrence or metastasis.
Discussion
The normal cystic duct connects the GB to the common
hepatic duct to form the CBD, and it is considered the
most important structure to be identified during chole-
cystectomy. The normal cystic duct usually measures 4
to 6 cm in length, and 1 to 5 mm in diameter.
During cholecystectomy, a variable length of cystic
duct is left as a remnant. The length of the normal cystic
duct measures 5 to 25 mm and the caliber is approxi-
mately 4 mm [4]. If the RCD is longer, RCD syndromeFigure 1 Findings on magnetic resonance cholangiopancreatography
stones; B: Focal enhancing of wall thickening in the remnant cystic duct adoccurs more frequently and long cystic duct stump can
be a site where gallstones can be formed “de novo” [5].
On the contrary, if the RCD is shorter, a benign CBD
stricture is more likely to occur. A RCD measuring lon-
ger than 1 cm is called a cystic duct remnant [6].
Cystic duct adenocarcinoma is a rare entity, and is
considered a GB cancer [7]. Although the risk factors
of GB cancer are being reported, those of cystic duct
adenocarcinoma were reported nil [8]. Cystic duct
adenocarcinoma is reported that it accounts for 8%
of the entire GB cancer [2]. The diagnosis of cystic duct
adenocarcinoma distinguishes primary cystic duct adeno-
carcinoma from secondary cystic duct adenocarcinoma
metastasized from GB cancer or cholangiocarcinoma. In
1951, Farrar et al. first described the diagnostic criteria
for cystic duct adenocarcinoma that included (a) growth
restricted to the cystic duct, (b) absence of neoplastic
process in the GB, hepatic, or CBD, and (c) histological
evidence of adenocarcinoma. According to these criteria,
primary cystic duct adenocarcinoma accounts for 2.6 to
12.6% of extrahepatic bile duct cancer and 1.5% of GB
cancer [7,9]. In 2003, Ozden et al. revised these criteria
and extended them in order to include advanced cases.
The new working definition of cystic duct adenocarcin-
oma describes cystic duct adenocarcinoma as a GB
tumor whose center is located in the cystic duct [10].
RCD cancer is now defined as a cystic duct adenocarcin-
oma occurring >5 years post-cholecystectomy [2]. In the
described case, the diagnosis matched both Farrar’s and
Ozden’s criteria.
Symptoms may develop earlier in cystic duct adeno-
carcinoma than in GB cancer. The anatomical structure
of cystic duct adenocarcinoma can lead to cystic duct
obstruction, which causes symptoms like abdominal
pain, jaundice, palpable mass due to GB distension, and
cholecystitis with fever, chills and other systemic inflam-
mation. These symptoms may aid in the early detection
of cystic duct adenocarcinoma [11]. Accordingly, early
detection is the reason why bile duct invasion, lymph
node metastasis, and distant metastasis are relatively. A: Inflammation in the remnant cystic duct with multiple impacted
jacent to the common bile duct.
Figure 2 Microscopic findings. A: Severe inflammation with atypical glands proliferation (Hematoxylin-eosin staining, original magnification ×100).
B: Atypical glands with invasive pattern, indicating adenocarcinoma (Hematoxylin-eosin staining, original magnification ×400).
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resectability rate in cystic duct adenocarcinoma was re-
ported to be close to 100%. On the other hand, the re-
sectability rate in extrahepatic bile duct or GB cancer is
less than 30%. This high resectability rate in cystic duct
adenocarcinoma has improved the prognosis. The median
survival period of cystic duct adenocarcinoma is longer
(20.2 months) than extrahepatic bile duct (3.2-11.4 months)
or GB cancer (5.8 months) [10].
However, as in the present case, patients who have
undergone cholecystectomy have late onset of symptoms
and early diagnosis may be difficult. Moreover, in this
case, the patient was advised to have removal of RCD
for incidentally detected RCD stones two years prior, but
she declined the surgery at that time. In advanced cystic
duct adenocarcinoma or cystic duct adenocarcinoma
with lymph node metastasis, there is no chance of a rad-
ical resection and the prognosis is poor. Therefore, early
diagnosis is very important [7].
As in this case, there have been more cases of patho-
logic diagnosis at the time of surgery or after surgery
rather than preoperative diagnosis. However, with the
development of diagnostic methods such as ERCP, mag-
netic resonance cholangiopancreatography, endoscopic
ultrasound, and intraductal ultrasound, more cases of
preoperative diagnosis have been reported recently [10].
Moreover, the evaluation of the extent of tumor infiltra-
tion through the bile duct wall prior the operation is
mandatory for planning curative surgery.
Although the lymph nodes and bile duct are not
usually involved in adenocarcinoma of the cystic duct,
cholecystectomy usually leads to an unsatisfactory out-
come, possibly due to bile duct invasion and perineural
invasion. Thus, the combined resection of the GB and
bile duct with lymph node dissection is the choice of
treatment for adenocarcinoma of the cystic duct, offer-
ing a better prognosis and higher survival rate, including
a higher chance of potential cure [12,13].
Despite the lack of randomized trials, many retrospective
articles have shown that postoperative adjuvant radiationtherapy is effective in increasing the overall survival in pa-
tients with GB or extrahepatic bile duct adenocarcinoma,
particularly those with positive surgical margins [14-16].
We therefore consider postoperative adjuvant radiation
therapy in cases of advanced cystic duct adenocarcinoma
with positive surgical margins, but more studies are needed
to establish its efficacy.Conclusion
In conclusion, we report a case of adenocarcinoma that
developed from the RCD in a patient who underwent
cholecystectomy 10 years ago. RCD cancer is extremely
rare; complete removal of the RCD and a second oper-
ation (confirmation of the resection margin of the RCD,
wedge resection of the liver, and lymphadenectomy)
were successfully performed under the suspicion of pT2.
The patient is still living 1 year after surgery without any
recurrence or metastasis. Finally, according to literature
data, the cystic duct stump should be made as short
as possible without impinging on the CBD in order to
avoid developing complications related to stasis of bile
in the retained cystic duct.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.
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